gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · WGSHealthcareHealth Services

GeneDx Holdings Corp. Class A Common Stock (WGS)

$64.36−7.18%
Close Nov 5, 2026 · split-adjusted
Nov 5, 2026$62.70▼ 55.05% in range
Nov 4, 2025Low $34.51 · High $167.51Nov 5, 2026
What changed · written from our data
As of Nov 5, 2026

GeneDx Holdings closed at $64.36 on Nov 5, down 7.18%, 61.6% below its 52-week closing high. Volume of 877.9K shares was 1.07× its 20-day average (close to normal).

Split-adjusted performance: -6.1% over one month, +58.9% over six months, -53.9% over one year.

In the quarter ended Jun 30, 2026, revenue was $114.44M, up 11.4% from a year earlier, with a net margin of -15.5%.

Short interest was 6.0M shares at the Oct 15 settlement, up 7.0% from the prior report (32.1% of float, 8.7 days to cover).

Market cap$1.92B29.8M shares
Revenue · quarter$114.4M+11.4% YoY
Diluted EPS$-0.60−266.7% YoY
P/E · TTM—P/S 4.2×
Net margin-15.5%Gross 68.4%
Dividend yieldNone
52-week range34.51 – 167.51−61.6% from high
Volume877.9K1.07× 20-day avg
Volatility · 60d80.1%Annualised
Short % of float32.1%8.7 days to cover
Net cash$35.7MCash $132.5M
Next earnings—Not scheduled
Split-adjusted performance
1W −9.4%1M −6.1%3M −16.5%6M +58.9%YTD −50.5%1Y −53.9%3Y +3360.2%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Health Services

Percentile among 20 companies (100 = best)

6-month momentum84
Revenue growth65
Net margin17
Value (low P/E)—
Size74

Industry medians: 6-month return +11.1%, revenue growth +7.2%, net margin 3.0%, P/E 72.1×.

Short interest

Details →
Shares short6.0M+7.0% vs prior
Days to cover8.7Settled Oct 15
% of float32.1%
Short vol. 10d61.7%of daily volume

Closest peers by size in Health Services

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
WGSGeneDx Holdings$64.36−7.18%+58.9%+11.4%−15.5%—$1.92B
AGLagilon health$113.77+18.23%+87.6%+5.9%2.3%—$1.91BCompare
USPHUS Physical Therapy$97.20+8.99%+64.7%+8.5%1.8%545.5$1.45BCompare
PNTGThe Pennant Group$40.00−9.17%+12.0%+35.8%3.0%43.2$1.40BCompare
PGNYProgyny$34.37+14.19%+79.4%+5.3%8.0%33.5$2.64BCompare
INNVInnovAge Holding$9.09−7.15%+12.5%+12.1%7.4%137.9$1.24BCompare
PRVAPrivia Health Group$23.94+6.88%−0.2%+21.4%1.4%108.7$3.06BCompare
OMDAOmada Health$18.95−2.47%+15.5%+43.1%6.0%269.5$1.16BCompare
SHCSotera Health$15.87−3.17%+1.3%+4.4%18.0%26.1$4.53BCompare

News about GeneDx Holdings

All news →
WGS DEADLINE MONDAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages GeneDx Holdings Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 3 Deadline in Securities Class Action - WGSGlobeNewswire Inc. · Aug 1, 2026▼ NegativeMONDAY DEADLINE: GeneDx Holdings Corp. (WGS) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP AnnouncesGlobeNewswire Inc. · Jul 31, 2026▼ NegativeGeneDx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against GeneDx Holdings Corp. - WGSGlobeNewswire Inc. · Jul 30, 2026▼ NegativeWGS DEADLINE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages GeneDx Holdings Corp. Investors to Secure Counsel Before Important August 3 Deadline in Securities Class Action - WGSGlobeNewswire Inc. · Jul 30, 2026▼ NegativeGeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLCGlobeNewswire Inc. · Jul 29, 2026▼ Negative

Quick answers

What does GeneDx Holdings do?
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive.
What is WGS's market cap?
$1.92B, based on the Nov 5 close of $64.36.
Does GeneDx Holdings pay a dividend?
No regular cash dividend has been paid in the last year.
How much of WGS is sold short?
6.0M shares, 32.1% of float, as of Oct 15, 2026.
What sector is WGS in?
Healthcare, in the Health Services industry.

About GeneDx Holdings

GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.

HQ: Stamford, CT1,300 employeesListed Jul 23, 2021genedx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology